Chemokine (C-C motif ) ligand 2 (CCL2) is a chemotactic cytokine recruiting monocytes, releasing growth factors and promoting adhesion in vascular endothelium. Elevated serum and urinary CCL2 levels and expression of its receptor (CCR2) have been associated with tumorigenesis in human urinary malignancies. CCL2 implication has not been investigated in canine urothelial carcinoma. The aim of this study was to evaluate CCL2 serum and urine levels (measured by ELISA) in dogs with urothelial carcinoma or non-neoplastic urinary tract disease. CCL2 serum and urine levels were significantly higher in diseased dogs compared with healthy dogs (P < 0.001). Dogs with carcinoma had significantly higher serum and urine CCL2 levels (P = 0.001) than healthy dogs. Dogs with metastases showed significantly lower serum and urine CCL2 levels compared with the non-metastasised tumour group (P = 0.007). CCL2 as a diagnostic marker for urothelial carcinoma held a sensitivity of 95.2% and a specificity of 38.2% in the urine. As a staging marker, sensitivity was 85.7% and specificity was 57.1% with a positive predictive value of 75.7% and a negative predictive value of 71.9%. Further investigation is needed to define the role of CCL2 as a prognostic marker in canine urothelial carcinoma.
| INTRODUCTION
Urothelial carcinoma (UCa) represents approximately 2% of all tumours affecting dogs. 1 Metastases have been reported in 16% of dogs at the time of diagnosis, and distant metastases were found in 58% of dogs at necropsy. 2 Prostatic carcinomas are mainly of urothelial origin. 3, 4 Prostatic carcinoma is highly metastatic with 80% dogs diagnosed with metastasis at necropsy. The treatment of UCa in dogs can be challenging because of a late diagnosis contributing to an extensive local invasion at the time of diagnosis.
There is sufficient proof that chronic inflammation predisposes individuals to development of various types of cancer, defining inflammation as a hallmark of cancer. 5, 6 An increase in inflammatory cells and soluble inflammatory mediators, such as cytokines and chemokines in the primary tumour, is mostly associated with poor prognosis because of metastasis. 7 However, the immune system has a dual role in cancer progression that depends on the cellular context of infiltrating cells and the tumour type. Chemokines and chemokine receptors have a key role in cancer-associated inflammation, where the chemokine-chemokine receptor axis affects both the composition and the function of cells within the tumour microenvironment.
In humans, several chemokines such as CXCL1, CXCL2, and CXCL12 have been reported to play a role in the development of the primary tumour or metastasis of urogenital tumours. Chemokine (C-C motif ) ligand 2 (CCL2) (previously named monocyte chemoattractant protein-1 or MCP-1) has been demonstrated to be highly expressed by tumour cells in different cancer types in humans. [8] [9] [10] [11] [12] [13] CCL2 serum and urinary level are increased in bladder and prostatic cancer in human patients. 11, 14 Roles of this chemokine include local tumour invasion, cell migration, tumour cell intravasation and extravasation. 15 By attracting tumour-associated macrophages, CCL2 promotes angiogenesis via the expression of pro-angiogenic factors such as vascular endothelial growth factor, 7 epidermal growth factor 16 and basic fibroblast growth factor-2. 17, 18 Moreover, when binding to its receptor CCR2 at the surface of endothelial cells, CCL2 induces cytoskeletal retraction within the vascular endothelial cells, forming a gap between cells and allowing transmigration of tumour cells into the bloodstream. 19 CCL2 is related to an increased migration activity of the tumour cells through the activation of protein kinase C and phosphorylation of paxillin. 13 The significance of the role of CCL2/CCR2 in the pathogenesis of bladder cancer is emphasized by the fact that humans with specific polymorphisms in the CCL2 and CCR2 genes are at increased risk of developing bladder cancer. 20 In human patients with urinary bladder carcinoma (UBC), urinary levels of CCL2 have been demonstrated to correlate significantly with stage and grade of the tumour and may be a prognostic marker for the natural course of the disease. 11 Stage T2-T4 UCas have a 3-to 4-fold higher mean CCL2 concentration in the urine compared with stage T1 carcinomas.
11
High-grade UCa cell lines have also demonstrated to produce in vitro high concentration of CCL2 reaching up to 22 700 pg/mL, whereas low-grade UCa line produced only few traces of CCL2.
13
CCL2 has been studied sparsely in dogs with cancer. In a retrospective study involving dogs with lymphoma, it was shown that peripheral neutrophil and monocyte counts as well as serum CCL2
concentrations were significantly elevated relative to healthy control animals, and that such increases were associated with a decreased disease-free interval in dogs treated with chemotherapy. 21 However, no study has evaluated CCL2 level in canine UCa.
Therefore, the aim of the study was to investigate urinary and serum CCL2 levels as potential biomarkers in canine UCa. We hypothesized that CCL2 levels in serum and urine would be higher in dogs with UCa compared with healthy animals and that dogs with metastasised UCa would have a higher CCL2 concentration compared with the nonmetastasized animals. Serial dilution (1:2 dilution, 1:4 dilution, 1:8 dilution) of the neat, spike and control samples were performed, and linearity was calculated according to the following formula:
| MATERIALS AND METHODS

| Dog population
where X represents the dilution.
Recovery was calculated according to the following formula:
2.4 | Immunoassay CCL2 concentrations were expressed in pg/ml for serum samples.
CCL2 concentration in the urine was reported as a CCL2: creatinine ratio to correct for dilution as reported in previous studies.
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| Statistical analysis
Prior to the study, power analysis was calculated based on the previous results of Perry et al 21 Using this SD with an alpha of 0.05, a power of 93% could be reached with a number of 10 dogs per group.
Normality of data was assessed using the Kolmogorov-Smirnov test.
Multivariate analysis was performed using a linear model including regression on weight, age, sex and disease status. The model was as follow: In this study, a diagnostic marker was defined as a marker able to differentiate animals with or without a carcinoma. A staging marker was defined as a marker able to differentiate overall if any metastasis (regional or distant metastasis) was deemed present.
| RESULTS
Seventy-nine dogs were included in the study. Ten female and 10 male Beagle dogs were included in the healthy group. Ten female and 6 male dogs were included in the bacterial cystitis group. Ten male dogs were included in the bacterial prostatitis group and 10 male dogs in the BPH group. Twenty-three dogs with UCa were included, seven female and seven male dogs in the metastasized UCa group, and nine female dogs in the non-metastasized UCa group. In the metastasized UCa group, all male dogs had involvement of both bladder and prostate except one dog that only had bladder involvement.
The inflammatory group included Beagle dogs (n = 5), crossbreed dogs (n = 4), Malinois Belgian Shepherds (n = 3), American
Staffordshire Terriers (n = 3), Jack Russel Terriers (n = 3), Bernese
Mountain dogs (n = 2), Belgian Griffons (n = 2), Golden Retrievers Among the metastasized UCa group, all dogs had metastasis to the sublumbar lymph nodes, one dog had hepatic metastasis and one dog had a lumbar vertebral metastasis (both confirmed with cytology).
| Validation of a canine CCL2 ELISA kit for urine samples
A linearity/recovery test was performed on urine samples. In our selected samples, recovery was 98% for the UCa sample, 120% for the cystitis sample and 114% for the healthy sample. Linearity ranged between 90% and 113%. These results allowed validating the use of this ELISA kit on canine urine samples.
| CCL2 concentration in serum
No significant influence of age, weight and gender was detected on CCL2 concentration in serum in all groups.
There was a significant difference in CCL2 concentration between healthy dogs and all urogenital tract diseased dogs (including inflammatory and neoplastic state) (P = 0.015), and between healthy dogs and dogs with UCa (metastasized or not) (P < 0.01) with a median value of 141.9 pg/mL (range: 69. 194.7-1841.6) (P < 0.01) (Figure 1 
| CCL2: creatinine ratio in urine
No significant influence of age, weight and gender was detected on CCL2: creatinine ratio in urine in all groups.
There was a significant difference between the urine CCL2: creatinine ratio in healthy dogs and all urogenital tract diseased dogs (including inflammatory and neoplastic state) (P < 0.001) and between healthy dogs and dogs with UCa (metastasized or not) (P < 0.01) with a median ratio of 2.9 × 10 −7 (range: 0.87 × 10 ) for all dogs with UCa.
No significant difference was found in urinary CCL2: creatinine ratio between dogs with non-neoplastic urogenital disease and dogs with UCa (P = 0.115).
There was also no significant difference (P = 0.493) in urinary CCL2: creatinine ratio among the bacterial cystitis, bacterial prostatitis and the BPH group with a respective median ratio of 27.1 × 10 There was a good correlation (r = 0.73; P < 0.01) between the serum CCL2 concentration and the urine CCL2: creatinine ratio (Figure 3 ). concentration as a diagnostic tool in serum is fair and poor in the urine; however, its accuracy in differentiating metastatic and nonmetastatic disease is good in the serum and fair in the urine. The exact mechanisms of this CCL2 increase in neoplasia and inflammatory state is yet unknown. Some reports suggest that CCL2 mobilization is mediated by inflammatory cytokines such as TNF and interleukins in humans. 27, 28 CCL2 increases in dogs with neoplasia could therefore be linked to the tumour inflammatory microenvironment.
| CCL2 as a diagnostic marker in the serum
In our study, age and weight did not influence CCL2 levels neither in the serum nor in the urine samples. This result contrasts with human literature where serum CCL2 concentration increased with age in healthy patients. 29 The reason of this age-dependant CCL2 level is FIGURE 5 Receiver operating characteristic curve and area under the curve (AUC) to differentiate between dogs with a urothelial carcinoma with metastasis and without metastasis using chemokine (C-C motif ) ligand 2 (CCL2) level in the serum (A) and in the urine (B). Youden index cutoff with their associated sensitivity (Se) and specificity (Sp) is presented for each curve [Colour figure can be viewed at wileyonlinelibrary.com]
Receiver operating characteristic curve and area under the curve (AUC) to differentiate between dogs with a urothelial carcinoma located in the bladder only with metastasis and without metastasis using chemokine (C-C motif ) ligand 2 (CCL2) level in the serum (A) and in the urine (B). Youden index cut-off with their associated sensitivity (Se) and specificity (Sp) is presented for each curve [Colour figure can be viewed at wileyonlinelibrary.com] unknown. It has been suggested that higher CCL2 concentration in elderly people may be due to a subclinical atherosclerosis or an agedependant shift between T-helper cell-dependent cytokine patterns. 29 The difference between our study and the latter may be due to species specificity. Extensive local invasion in UCa is often observed because of late diagnosis. In humans, invasive work-up (such as cystoscopy or biopsies) is needed in order to detect local recurrence. This has led to the search for biomarkers helping in the early detection of the disease or its recurrence. In humans, four urinary biomarkers have been validated for UCa: the nuclear matrix protein 22 (NMP-22; Se = 61.8%, Sp = 80.3%), the bladder tumour antigen (BTA; Se = 64%, Sp = 76%), the cytokeratin-based test UBC antigen (Se = 64.4%, Sp = 80.3%) and the Cyfra 21-1 (Se = 64.4%, Sp = 85.5%). 30 All these markers have a higher sensitivity than urine cytology in humans. However, the sensitivity stays lower than the cystoscopy, which is considered in human medicine as a standard to detect recurrence of bladder tumour. In veterinary medicine, the search for biomarkers has also gained popularity. Cytology, as in human medicine, has a low sensitivity and specificity. BRAF V595E mutation in the urine detected with digital droplet polymerase chain reaction (ddPCR) has been described. 29 The V595E mutation has been reported in 87% of UCa.
The use of ddPCR has shown an 85% sensitivity and a 100% specificity in free catch urine. 31 In canine UCa, it has also been reported that three regions of the canine genome were subject to recurrent copy number changes. These copy number imbalances were detected in 67% of urine samples. 32 A multiplex biomarker approach suggested four proteins as potential biomarkers (macrophage capping protein, PRX1, PRX6 and ribonucleoprotein A2/B1), but further studies would be needed to assess their sensitivity and specificity. 33 The BTA test validated in humans showed in canine samples (v-BTA) a high false positive rate with a PPV of only 2.8% and an NPV of 100%. 34 Detection of urine canine calgranulin S100A 8 /A 9USG showed a PPV of 3%
and an NPV of 100% (Se = 86%; Sp = 80%). In our study, serum CCL2 or urinary CCL2: creatinine ratio as diagnostic biomarkers showed a similar trend with nearly 100% of dogs with a negative test having no carcinoma (NPV = 90.4% and 99.7%, respectively), while the PPV was only 10.3% and 3%, respectively. As such, the use of CCL2 level both in serum and urine as a sole diagnostic test would not be indicated for detecting canine UCa but could help to exclude UCa. In humans, the use of urine CCL2 level as a sole diagnostic test had a 14.8% sensitivity and a 96% specificity. However, a combined assay with NMP-22, urinary intercellular adhesion molecule, CCL2 and cytology had a 80% sensitivity and a 100% specificity in muscle invasive bladder tumours (PPV = 100%; NPV = 99.6%). 12 The lower sensitivity and higher specificity in human urine CCL2 compared with canine urine test is not fully understood. Its increased level is also associated with a worse overall prognosis in prostatic carcinoma in humans. 35 In in vitro studies and in mouse models, CCL2 has been reported to facilitate metastasis in different cancer type in humans. [36] [37] [38] In our study, the use of CCL2 level in serum and urine leads to a good PPV and NPV.
Serum CCL2 test had a PPV of 86.6% and an NPV of 81.9%. Urine CCL2: creatinine ratio had a PPV of 75.5% and an NPV of 71.9%.
Interestingly, in our study, we found that a low level of CCL2 was associated with metastasis. The role of CCL2 in tumorigenesis is unclear. In humans, although an increased CCL2 levels has been associated with metastasis facilitation, other studies support the evidence that CCL2 increase may be correlated with metastasis suppression.
Overexpression of CCL2 in murine colon carcinoma showed a suppression of metastatic process 39 and a high level of CCL2 has been reported to be a favourable prognostic factor for pancreatic carcinoma in humans. 40 In human pancreatic carcinoma, high levels of serum CCL2 were associated with a low Ki-67. High levels of serum CCL2 were also correlated with an increased iNOS concentration among tumour cell cultures generating NO, thus inducing G1 phase arrest and apoptosis. 40 Monti et al 40 suggested that CCL2 may not be indispensable but may favour tumour death by two possible mechanisms: massive monocyte/macrophage recruitment into the tumour and/or an increased NO production inducing apoptosis.
Our study aim was to assess if CCL2 would be a good biomarker for UCa in dogs. It would be interesting to correlate CCL2 level with macrophages invasion and to investigate potential factors which may influence CCL2 production and whether this may enhance or inhibit tumour progression in canine UCa.
Limitations of this study include the lack of male dogs in the nonmetastasized group. Unfortunately, no male dog with UCa was presented in our hospital without any metastasis during the study period.
Although males were not present in the non-metastasized group, gender was not found to influence CCL2 concentration in the other different groups. Further study would be needed to compare nonmetastasized UCa located in the bladder and the one located in both bladder and prostate.
In our study, the healthy group included only Beagle dogs bred in specific facilities. Although this choice allows a better standardized group, an ideal control group would have included client-owned dogs of different breeds. One previous study demonstrated breedspecificity in CCL2 serum concentration among healthy dogs. 43 Healthy West Highland White Terriers were reported to have a higher serum CCL2 level when compared with healthy Maltese or Malinois
Belgian Shepherd. 43 However, CCL2 concentration in our Beagle dogs was within the range reported for all breeds in this study.
Histology was not performed in all primary tumours, and only cytology was performed on regional lymph nodes for staging pur- In conclusion, the results of this study indicate that CCL2 in serum and urine as sole diagnostic tool could not be used to differentiate UCa from other urogenital diseases in dogs. In this study, a low level of CCL2 was associated with metastasis in dogs with UCa affecting the bladder. CCL2 level in serum and urine may be of importance during staging in dogs with bladder UCa. However, further investigation is needed to confirm these findings and further studies are needed to investigate the role of CCL2 in canine urothelial tumours as well as its additional value during staging.
